

Thursday 2nd Oct 2025



Today's issue of *PD*

Pharmacy Daily today features four pages of news, including our Beauty & Wellness feature, plus a full page from Dispense Assist.

Dispensary help

DISPENSE Assist is a low-cost staffing solution with dispensary technicians available 24/7, at rates from as low as \$8.94 per hour, for services that include compounding, DAAs and any other required tasks. Details on page five.

Save with APP2026 Tier 1 pricing

APP2026 is offering a three-tiered registration pricing structure to help improve affordability.

Tier 1, the greatest value option, offers delegates a saving of up to \$250 on full registration and is available until 31 Oct 2025, after which Tier 2 pricing will apply, with a saving of \$140 - more HERE.

WA kids to get intranasal flu vax

THE Western Australian Government has announced it will provide the FluMist intranasal influenza vaccine for children aged two to 12 years next year ahead of the 2026 flu season, a move welcomed by the Pharmaceutical Society of Australia (PSA).

The initiative aims to boost childhood vaccination rates and reduce flu-related illness and hospitalisations across the state. with PSA WA President Kristian Ray saying pharmacists are ready to support the rollout.

"This is a game-changer for children who experience needle anxiety," Ray said.

"Pharmacists are integral to improving immunisation rates and reducing pressure on our health system, and we look forward to working with the WA Government to deliver this important public health initiative."

Western Australia has now joined Queensland, New South Wales and South Australia in providing the needle-free vaccine for children, with the Royal Australian College of GPs calling for the Victorian and ACT governments to follow suit.

PSA National President Associate Professor Fei Sim said the WA



Government's decision showed leadership and commitment to prioritise children's health, and called on all state and territory governments to legislate "so every child, no matter their postcode, can access free, convenient, and needle-free protection".

"We note that FluMist is currently being considered by the Pharmaceutical Benefits Advisory Committee for the National Immunisation Program," Assoc Prof

"Federal funding will be critical for national consistency, but until then, states and territories must step up to protect children against this vaccine-preventable disease."

The PSA will deliver a dedicated webinar, a quick reference guide, and learning module around implementing intranasal influenza vaccination this month. KB

FIP hypertension toolkit launched

THE International Pharmaceutical Federation (FIP) has launched a new Hypertension Pharmacy Toolkit, designed to support pharmacy teams in the prevention, early detection and management of hypertension.

The condition affects one in three adults worldwide, and contributes to over 10 million deaths each year.

The toolkit equips community pharmacy teams with practical resources to identify at-risk patients, deliver motivational counselling and collaborate effectively with prescribers to improve patient outcomes.

"This toolkit was developed to motivate and enable community pharmacy teams to establish or strengthen hypertension assessment and management programs in their communities, building on their accessibility and expertise in medication management and lifestyle counselling," said Dr Ines Nunes da Cunha, FIP Practice Development Manager - the toolkit is HERE.

IMPORTANT ANNOUNCEMENT



We have Just introduced New System. Smarter Security. Better Experience We've just launched a new system designed to protect sellers and streamline the buyer journey.

For Pharmacy Sellers: List your pharmacy with confidence. Our upgraded platform ensures your Information Memorandum (IM) is secure—no printing, no sharing-so sensitive details stay protected and out of the wrong hands.

Buyers-Why Not Register Today? Skip the wait and get straight to the opportunities. Once you sign up you'll receive a secure link to set your own password and access your member dashboard.

Whether you're selling or buying, we're making pharmacy transactions safer and smoother than ever.



U 0407 759 736 sue.raven@srpbs.com.au 🐞 www.srpbs.com.au





Supplied by

Trusted by Australian pharmacies.

DNP DST10 'ALL IN ONE' SNAPLAB

The all-in-one photo kiosk Australia trusts. Compact & intuitive. Ideal for pharmacy.





Thursday 2nd Oct 2025





ORDER HERE

Fallout from Choice sunscreen testing continues

THE Therapeutic Goods
Administration (TGA) has confirmed that 20 sunscreens sold in Australia are using the same base formula as Ultra Violette's Lean Screen, which rated SPF 4 in the Choice sunscreen tests earlier this year (PD 12 Jun), and expressed concerns with the UK testing lab used to provide initial SPF ratings.

Lean Screen was manufactured using the same base formulation as a number of other sunscreens, and the manufacturer of that base formulation, Wild Child Laboratories, has now received preliminary SPF testing results for that base formulation.

The preliminary testing indicates that this base formulation is unlikely to have an SPF greater than 21 and, as with Lean Screen, may be as low as SPF 4.

Brands whose range includes affected products are:

- Aspect Sun
- Aesthetics Rx
- New Day Skin

- Allganics
- Beauti-FLTR
- Found My SKin
- Ethical Zinc
- Endota
- We are Feel Good Inc
- GlindaWand
- Ultra Violette
- People4Ocean
- McoBeauty
- Naked Sundays
- Outside Beauty & SKincare
- Salus

The complete list of products and current status is **HERE**.

The Wild Child Laboratories has ceased manufacture and supply of the base formulation.

"It's highly concerning to see the TGA confirm that 20 sunscreens using the same base formula as Ultra Violette's Lean Screen are unlikely to meet their SPF claims," said Choice CEO Ashley de Silva.

"If you're currently using one of the sunscreens that shares this base formula, the TGA is advising you to consider trying out a different product as we head into hotter months.

"If you've been burnt while using one of these products - or any sunscreen - consider reporting your experience to the TGA," he added.

The TGA also raised concerns around the reliability of Princeton Consumer Research Corp (PCR), a test lab based in the UK used by at least 15 sunscreens sold in Australia.

Two former employees of the company appeared on ABC's 7.30 yesterday outlining issues around questionable accuracy of data and incorrect testing practices, saying they left the company due to ethical concerns.

The TGA has notified all companies responsible for affected sunscreens of this testing and its concerns about the reliability of testing performed by PCR, and is considering whether to take



regulatory action with respect to those sunscreens.

Sunscreen brands Cancer Council, Woolworths and Ultra Violette, as well as base formulation manufacturers Baxter Laboratories and Wild Child Laboratories, told the ABC they are no longer using PCR to certify the SPF of their products.

The TGA has reiterated that despite concerns over the accuracy of testing, it is important that Australians continue to use sunscreens to protect against the harmful effects of UV radiation. KB

Save Time. Save Money.

Time to rethink your dispensary set-up?

The latest in pharmacy robotic automation from Willach Pharmacy Solutions:

- State-of-the-art technology
- Automated loading creates efficiency
- Advanced diagnostic support
- Sophisticated reporting and ordering software - saves time and improves your cashflow.

find out more







Beauty Wellness

Thursday 2nd Oct 2025 advertising@pharmacydaily.com.au

Editor's Choice: Bioderma's new anti-redness range soothes the skin

ROSACEA sufferers can now try Bioderma's new Sensibio AR+ range, a new anti-redness range the skincare brand has developed alongside dermatologists.

Formulated with Bioderma's new patented technology called Rosactiv 2.0, the range aims to soothe redness caused by a range of triggers such as menopause, puberty, rosacea, pregnancy, climate, food reactions and more.

Hero products include the Sensibio AR+ Cream (RRP \$42.99), a daily moisturiser with a new formulation to calm skin and reduce visible redness while protecting the barrier.

Meanwhile, the Sensibio AR+ SOS Spray (RRP \$22.99) is an



ultra-fine mist designed to relieve sensations of overheating in just Available now at Priceline, Chemist Warehouse and select retailers around Australia.

10 seconds, Bioderma said. retailers around Australia.

CeraVe stays sun-safe

JUST in time for summer, CeraVe has released its Facial Moisturising Lotion with SPF50 (RRP \$26.99), formulated with ceramides, hyaluronic acid and niacinamide to nourish and protect the skin.

Suitable for normal to dry skin.
According to research from the
Australian Bureau of Statistics,
only two in five Aussies use
sunscreen on most days.



New 1000 Hour two-in-one trimmer set



AUSTRALIAN brow brand 1000 Hour makes grooming easy with its new two-in-one Trimmer Set (RRP \$34.99).

The new set features two interchangeable heads to easily

switch between trimming and gentle facial hair removal: the brow trimming head helps to shape and define brows, while the floating shaving head helps to remove unwanted hair from delicate areas.

It also features a built-in LED light for precision and accuracy and stainless-steel blades for safe, gentle trimming on sensitive skin.

Ideal for brows, upper lip, chin and other facial areas and suitable for sensitive skin.

1000 Hour has been offering Australians brow and lash products for more than 30 years, including its Lash & Brow Dye Kit (RRP \$19.99), 3-in-1 Brow Pencil (RRP \$19.99), Brow Cushion Duo (RRP \$24.99) and more.

For stockist information, contact info@chemcorp.com.au.

Fragrance dupes for men



AFFORDABLE Aussie beauty label Designer Brands has launched a range of dupes of iconic men's fragrances (RRP \$12.99 each), inspired by luxury labels such as Acqua di Parma, with prices in excess of \$300.

"We wanted to show that smelling incredible doesn't have to cost a fortune," said Amanda Connors, Global Chief Marketing Officer at Total Beauty Network.

"Our new men's fragrance range is luxurious, long-lasting and crafted with care.

"It's everything you'd expect from a high-end perfume, without the high-end price."

Aqua di Italiana is a new citrus fragrance, featuring notes of fresh Silician lemon, lavender and wood, while Super Homme is a crispy wood aromatic and On the Vine is a blend of cypress, ripened grapefruit and amber.

All Designer Brands fragrances are vegan and cruelty-free.

Available now in community pharmacies and online.

Want to feature on this page?

email advertising@pharmacydaily.com.au to find out more

Beauty Wellness by Pharmacy Daily



Thursday 2nd Oct 2025

HEALTH PROFESSIONAL?

Subscribe for free to receive our Health Professional only editions of Pharmacy Daily.

Click here to update your details





Dispensary Corner

A BRITISH YouTuber has discovered that the "acid reflux" he had been living with for 12 years or longer was in fact a rare swallowing disorder called oesophageal achalasia.

The condition affects fewer than 12 in 100,000 people and causes paralysis in the oesophagus, such that food can't enter the stomach.


Alfie Deyes, who is 32, said that some of his 3.6 million followers noticed he was losing weight and looking frail, and admitted he had been struggling with eating for years.

He finally consulted a doctor who specialises in swallowing disorders and underwent a barium swallow test, where the problem was quickly identified.

The disorder meant that food would literally get stuck in his throat, unable to get through the lower oesophageal sphincter, and after one mouthful he struggled to eat any more, he said.

The food would slowly work its way through the sphincter, but he was unable to eat enough to maintain his weight.

After the diagnosis, he underwent a simple procedure to loosen the sphincter muscle and make eating normally possible again.



"Vaccine champ" recognised

KERRY Savas (pictured), Principal Pharmacist at National Pharmacies Glenelg, has received the 2025 World Pharmacist Day Excellence Award for his "outstanding frontline work" in the vaccination space.

The awards were newly introduced by the South Australian Office of the Chief Pharmacist with the aim of celebrating the vital role of pharmacists in patient care, community health and the broader SA health system following the rollout of expanded pharmacy services such as urinary tract infection (UTI) consultations and travel vaccinations.

Savas has provided more than 1,500 vaccines in the last 12 months while also proactively ensuring patients are up to date with all required vaccinations.

He also led a successful travel vaccine service pilot for National Pharmacies earlier this year, which has now expanded into stores in SA and Victoria.

Savas said he was honoured to receive the award.

"Pharmacists do far more than



dispense medicine - in community pharmacy, we prioritise the health of every patient and the wider community," he explained.

In congratulating Savas, National Pharmacies CEO Mark Smith said, "Our pharmacists, like Mr Savas, are community health experts who use an evidence-based approach which not only boosts individual and community health and wellbeing, but also helps ease pressure on busy GPs and hospitals."

Smith also thanked the State Government for its continuing expansion of pharmacists' scope of practice, which has made services like travel vaccination more accessible, convenient and efficient for more South Australians.

Pfizer declines AD drug PBS listing

PFIZER has decided not to go ahead with the listing of atopic dermatitis drug Cibinqo (abrocitinib) on the Pharmaceutical Benefits Scheme (PBS), citing economic considerations.

The listing was recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) in Nov 2024, but Pfizer determined that the expected net price level and the current Risk Share Arrangement (RSA) would make the PBS listing commercially unsustainable for the company.

It also said the average selling price for Cibinqo "does not reflect the value of innovation", and while recognising that the RSA framework is intended to help limit government expenditure, it also limits patients' access to therapies.

"This decision represents a significant setback for consumers, patient advocacy groups, and healthcare professionals who continue to emphasise the critical need for more treatment options for those living with severe atopic dermatitis," said a Pfizer spokesperson.

"Australia must urgently create more flexible, patient-focused reimbursement that balances economic considerations with patient needs," they continued.

"Pfizer Australia joins industry, patients and healthcare professionals in calling for reform to Australia's Health Technology Assessment (HTA) to ensure patients can access the latest treatments when they need them."

Adam Spencer to speak at APP2026

RENOWNED mathematician, broadcaster and artificial intelligence (AI) expert Adam Spencer (pictured) will join the Australian Pharmacy Professional Conference (APP2026) speaker lineup to head a session on the emerging technology.

The session is intended to empower attendees to embrace Al and harness its potential to enhance pharmacy practice and future-proof their businesses.

"We're thrilled to welcome Adam Spencer to APP2026," said conference convenor Kos Sclavos. "Adam's ability to demystify complex technologies and make them accessible to everyday professionals is second to none.

"His insights into the Al revolution will be invaluable for pharmacy professionals navigating a rapidly evolving landscape," he added.



www.pharmacydaily.com.au

Pharmacy Daily is part of the Business Publishing Group family of publications.

Pharmacy Daily is Australia's favourite pharmacy industry publication.

EDITORIAL
Editor - Karina Bray
Deputy Editor - Matt Lennon
Journalists - Adam Bishop, Myles
Stedman, Janie Medbury
Editor-at-large - Bruce Piper
Associate Publisher - Jo-Anne Hui-Miller

Editorial Director - Damian Francis

ADVERTISING AND MARKETING
Head of Sales & Marketing
Sean Harrigan
advertising@pharmacvdailv.com.au

GENERAL MANAGER & PUBLISHER

Matthew Vince

ACCOUNTS

accounts@traveldaily.com.au

Suite 1, Level 2, 64 Talavera Rd Macquarie Park NSW 2113 Australia Tel: 1300 799 220 (+61 2 8007 6760)

info@pharmacydaily.com.au



Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Damian Francis.



STAFF SHORTAGES? OVER-WORKED? WAGES INCREASING?

GIVE YOUR DISPENSARY THE HELP IT NEEDS

Dispense Assist is a revolutionary way of dispensing prescriptions in your pharmacy for a fraction of your normal cost.



Utilising the latest technology, software and security, Dispense Assist technicians work on your workstation to dispense prescriptions and perform any other task you require.



We are available 24/7/365 at a moment's notice whenever needed for sessions of 30mins to 24hrs.

Rates as low as \$8.94 per hour with the same rates for days, nights, weekends and public holidays.

PERFECT FOR DISPENSING AND OTHER TASKS FOR:



DAA



Compounding



Cannabis



Private Hospitals



Online Sales



eScripts

and much more

Curious to see if it's a fit for your pharmacy?

Sign up for a FREE Trial Now:



